β2 adrenergic receptor antag 
Welcome,         Profile    Billing    Logout  
 1 Company  1 Product   1 Product   0 Diseases   2 Trials   6 News 
  • ||||||||||  Sympathetic modulation of the immune microenvironment in lung tumors (WCC Halls A-C) -  Nov 3, 2023 - Abstract #Neuroscience2023NEUROSCIENCE_12115;    
    Moreover, we demonstrate that the ?2-adrenergic receptor antagonist can potentiate the anti-PD-L1 immunotherapy of lung cancer in mice. Together, these results have elucidated the sympathetic modulation of the immune microenvironment in lung cancer, providing a novel target for effective treatments.
  • ||||||||||  dizocilpine (MK801) / Merck (MSD)
    Cold nociception as a measure of hyperalgesia during spontaneous heroin withdrawal in mice (WCC 201) -  Nov 3, 2023 - Abstract #Neuroscience2023NEUROSCIENCE_1089;    
    Together, these results have elucidated the sympathetic modulation of the immune microenvironment in lung cancer, providing a novel target for effective treatments. To pharmacologically characterize the stable cold plate test, we used
  • ||||||||||  epinephrine / Generic mfg.
    Journal:  The β2-adrenergic receptor in the apical membrane of intestinal enterocytes senses sugars to stimulate glucose uptake from the gut. (Pubmed Central) -  Jan 27, 2023   
    Most adrenergic receptor antagonists inhibit sugar signaling, while some differentially inhibit epinephrine and sugar responses...Oral administration of glucose with a non-bioavailable β -AR antagonist lowered the subsequent increase in blood glucose levels, confirming a role for enterocyte apical β -ARs in stimulating gut glucose uptake, and suggesting enterocyte β -AR as novel drug target in diabetic and obese patients. Future work will have to reveal how glucose sensing by enterocytes and neuroendocrine cells is connected, and whether β -ARs mediate glucose sensing also in other tissues.
  • ||||||||||  erlotinib / Generic mfg.
    CYSTIC LUNG DISEASE IN A PATIENT WITH METASTATIC LUNG ADENOCARCINOMA TREATED WITH LONG-TERM ERLOTINIB (Convention Center Exhibit Hall: Poster Area) -  Aug 16, 2022 - Abstract #CHEST2022CHEST_1878;    
    She subsequently completed six cycles of carboplatin and pemetrexed chemotherapy...She was started on second line immune checkpoint inhibitor therapy with pembrolizumab but was unable to tolerate it due to severe headaches and subsequently switched to alternative immunotherapy with atezolizumab...Later imaging demonstrated disease progression and patient transitioned to palliative chemotherapy with docetaxel... Given the increased use of EGFR-TKIs in the treatment of NSCLC, further studies are needed to explore the use of pulmonary toxicities from these chemotherapy agents especially the development of cystic lung disease.
  • ||||||||||  propranolol / Generic mfg.
    Journal:  Blockade of β2-Adrenergic Receptor Reduces Inflammation and Oxidative Stress in Clear Cell Renal Cell Carcinoma. (Pubmed Central) -  Mar 11, 2022   
    In the present study, we wanted to look deep into the effects of the ADRB2 blockers propranolol and ICI-118,551 on two main aspects of cancer progression: (i) the changes on the inflammatory response of ccRCC cells; and (ii) the modulation on the Warburg effect (glycolytic metabolism), concretely, on the expression of genes involved in the cell reactive oxygen species (ROS) balance and levels...The obtained results show that ADRB2 blockade in ccRCC cells reduces the level of oxidative stress and stabilizes the inflammatory response. Thus, these data further support the idea of targeting ADRB2 as a promising strategy for the treatment of VHL and other non-VHL tumors.
  • ||||||||||  SCH-23390 / Boehringer Ingelheim
    Journal:  Interconnection between Adrenergic and Dopaminergic Systems in Feeding Behavior in Neonatal Chicks. (Pubmed Central) -  Oct 27, 2021   
    In the first experiment, chickens received the intracerebroventricular (ICV) injection of a control solution, prazosin (i.e., α1 adrenergic receptor antagonist; 10 nmol), dopamine (DA; 40 nmol), and prazosin plus DA...In the seventh experiment, the birds were injected with the control solution, SCH23390 (i.e., D1 DAergic receptor antagonist; 5 nmol), NA (300 nmol), and SCH23390 plus NA In the eighth experiment, the control solution, AMI-193 (i.e., D2 DAergic receptor antagonist; 5 nmol), NA (300 nmol), and AMI-193 plus NA were injected...The co-injection of AMI-193 plus NA diminished NA-induced hypophagia, compared to that reported for the control group (p <0.05). The aforementioned results suggested that there is an interconnection between central DAergic and noradrenergic systems through α2/β2 adrenergic and D1/D2 DAergic receptors in food intake regulation in neonatal chicks.
  • ||||||||||  propranolol / Generic mfg.
    Journal:  Metoprolol decreases retention of fear memory and facilitates long-term depression in lateral amygdala. (Pubmed Central) -  Aug 4, 2021   
    Propranolol is suggested to be effective as a fear-reducing agent when paired with behavioral therapy soon after trauma when psychological stress is high, possibly dampening or preventing the later development of posttraumatic stress disorder...Intra-amygdala infusion of metoprolol not butoxamine attenuated reactivation-induced enhancement of fear retention. Our results suggest that β1-adrenergic receptor antagonist-metoprolol may be more suitable for the treatment of posttraumatic stress disorder.
  • ||||||||||  Lopressor (metoprolol tartrate) / Novartis
    Preclinical, Journal:  Ganoderic acid A protects neural cells against NO stress injury in vitro via stimulating β adrenergic receptors. (Pubmed Central) -  Dec 23, 2020   
    The addition of β1-adrenergic receptor antagonist metoprolol (10 μM) or β2-adrenergic receptor antagonist ICI 118551 (0.1 μM) blocked the protective effect of GA A, whereas the addition of α-adrenergic receptor antagonist phentolamine (0.1 μM) did not affect GA A protection in SH-SY5Y cells. These results suggest that β-adrenergic receptors play an important role in the protection of GA A in SH-SY5Y cells against SNP injuries, and excessive adrenaline system activation caused great damage to the nervous system.
  • ||||||||||  propranolol ER / Generic mfg.
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Propranolol in Treating Hypoglycemia Unawareness (clinicaltrials.gov) -  Jun 9, 2020   
    P2,  N=2, Terminated, 
    These results suggest that β-adrenergic receptors play an important role in the protection of GA A in SH-SY5Y cells against SNP injuries, and excessive adrenaline system activation caused great damage to the nervous system. N=12 --> 2 | Trial completion date: Jul 2020 --> Dec 2019 | Recruiting --> Terminated | Trial primary completion date: Jul 2020 --> Dec 2019; Statistical power could not be achieved due to low enrollment.
  • ||||||||||  propranolol ER / Generic mfg.
    Trial completion date, Trial primary completion date:  Propranolol in Treating Hypoglycemia Unawareness (clinicaltrials.gov) -  Jun 7, 2019   
    P2,  N=12, Recruiting, 
    The potential mechanisms of propranolol inhibit melanoma progression primarily by activating CD8+ T cells and inhibiting AKT/MAPK pathway via beta-2 adrenergic receptors. Trial completion date: Jul 2019 --> Jul 2020 | Trial primary completion date: Jul 2019 --> Jul 2020
  • ||||||||||  propranolol ER / Generic mfg.
    Trial completion date, Trial primary completion date:  Propranolol in Treating Hypoglycemia Unawareness (clinicaltrials.gov) -  Jul 10, 2018   
    P2,  N=12, Recruiting, 
    Trial completion date: Aug 2018 --> Jun 2019 | Trial primary completion date: Aug 2018 --> Mar 2019 Trial completion date: Nov 2018 --> Jul 2019 | Trial primary completion date: Nov 2018 --> Jul 2019
  • ||||||||||  propranolol ER / Generic mfg.
    Enrollment open:  Propranolol in Treating Hypoglycemia Unawareness (clinicaltrials.gov) -  Oct 27, 2017   
    P2,  N=10, Recruiting, 
    Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2019 --> Aug 2018 Not yet recruiting --> Recruiting